Australian Government - Department of Health and Ageing

Medical Services Advisory Committee (MSAC)

Reference 12b

Human papillomavirus testing in women with cytological prediction of low-grade abnormality

Human papillomavirus testing in women with cytological prediction of low-grade abnormality

Reference No.

12b

Reference NameHuman papillomavirus testing in women with cytological prediction of low-grade abnormality
Advisory PanelProfessor Brendon Kearney
(Chair and MSAC member)
Professor Sydney Bell
(MSAC member)
Dr Paul Craft
(MSAC member)
Dr Ray Kirk
(MSAC member)
Dr Dwina Dobriansky
(Royal Australian and New Zealand College of Obstetricians and Gynaecologists nominee)
Dr Annabelle Farnsworth
(Department of Health and Ageing - member until 7 August 2002)
Dr Alistair Lochhead
(Royal College of Pathologists of Australasia nominee)
Dr Heather Mitchell
(co-opted member)
Dr Marion Saville
(Australian Society of Cytology nominee)
Dr Judy Straton
(Department of Health and Ageing)
Dr Lynnette Wray
(Royal Australian College of Cytology nominee)
Ms Kathleen Mazzella
(Consumers' Health Forum of Australia nominee)
Date Received by MSAC SecretariatJune 2001
Stage 1 - EligibilityEligible
Stage 2 - AssessmentCompleted
Stage 3 - Formulation of Advice to the MinisterThis assessment was considered by the MSAC at the 21 August 2002 meeting.

Since there is currently insufficient evidence pertaining to the use of human papillomavirus NAA test for triaging of women with equivocal cervical screening results, the MSAC recommended that public funding should not be supported at this time for this diagnostic procedure.
Stage 4 - DecisionEndorsed by the Minister for Health and Ageing 16 October 2002
Stage 5 - Implementation

Page currency, Latest update: 30 March, 2009